Functionalized nanoparticles containing MKP-1 agonists reduce periodontal bone loss

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Periodontology

Background:

• Mitogen-activated protein kinase phosphatase (MKP) plays a key role in regulating periodontal inflammation.
• Recent advancements highlight MKP's potential in developing novel treatments for periodontal diseases.
• This study investigates nanoparticle-based delivery of an MKP-inducing agent for periodontal therapy.

Purpose of the Study:

• To evaluate the clinical utility of nanoparticles loaded with auranofin (ARN) for managing periodontal inflammation and alveolar bone loss.
• To determine if ARN-loaded nanoparticles (ARN-NPs) can effectively induce mitogen-activated protein kinase phosphatase (MKP)-1 expression.
• To assess the therapeutic potential of ARN-NPs in preclinical models of periodontitis.

Main Methods:

• Polyethylene glycol-polylactide (PEG-PLA) nanoparticles were loaded with auranofin (ARN).
• In vitro and in vivo studies were conducted to assess ARN-NP efficacy, including cytotoxicity, MKP-1 induction, macrophage uptake, and alveolar bone loss in a rat model.
• High-performance liquid chromatography (HPLC), quantitative polymerase chain reaction (qPCR), flow cytometry, and microcomputed tomography were utilized.

Main Results:

• ARN-NPs exhibited reduced cytotoxicity compared to free ARN.
• ARN-NPs significantly increased dual specificity protein phosphatase (Dusp)-1 mRNA and MKP-1 activity in vitro.
• In vivo studies showed significant reduction in lipopolysaccharide-induced alveolar bone loss in rats treated with ARN-NPs.

Conclusions:

• ARN-functionalized nanoparticles possess significant anti-inflammatory properties.
• ARN-NPs represent a promising novel adjuvant therapeutic strategy for periodontitis.
• This approach may lead to improved therapeutic outcomes for periodontal disease management.